Within the past week Pfizer has revived its plans to acquire AstraZeneca and may make a public declaration of its interest this week, Bloomberg and the Financial Times reported. People familiar with the matter told the latter that a bid could come in at over $100bn, versus the UK group's current market capitalisation of $86.6bn.Bloomberg data shows that the average premium for pharmaceutical takeovers - for transactions with a value of over $1bn - has been 30% over the last five years. AstraZeneca ended the Friday session with a market value of £51,448bn ($86.4bn) according to Digital Look data. Last week the stock made an attempt to break technical resistance at 4,142p. AB